131I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with 177Lu-DOTATATE peptide receptor radionuclide therapy

被引：0
|
作者：
Rahul V. Parghane
Sanjay Talole
Sandip Basu
机构：
[1] Bhabha Atomic Research Centre,Radiation Medicine Centre
[2] Tata Memorial Hospital Annexe,Section of Biostatistics
[3] Homi Bhabha National Institute,undefined
[4] Tata Memorial Centre,undefined
来源：
Annals of Nuclear Medicine | 2021年 / 35卷
关键词：
Paraganglioma (PGL); Peptide receptor radionuclide therapy (PRRT); Lu-DOTATATE; I-MIBG therapy; Neuroendocrine tumors (NETs);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：92 / 101
页数：9
相关论文
共 50 条
  • [1] 131I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with 177Lu-DOTATATE peptide receptor radionuclide therapy
    Parghane, Rahul V.
    Talole, Sanjay
    Basu, Sandip
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (01) : 92 - 101
  • [2] Peptide Receptor Radionuclide Therapy by 177Lu-DOTATATE of a Secreting Cervical Paraganglioma
    Deville, Agathe
    Pinigina, Iuliia
    Al Mansour, Laure
    Abeillon, Juliette
    Tordo, Jeremie
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (01) : E71 - E73
  • [3] High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma
    Jha, Abhishek
    Taieb, David
    Carrasquillo, Jorge A.
    Pryma, Daniel A.
    Patel, Mayank
    Millo, Corina
    de Herder, Wouter W.
    Del Rivero, Jaydira
    Crona, Joakim
    Shulkin, Barry L.
    Virgolini, Irene
    Chen, Alice P.
    Mittal, Bhagwant R.
    Basu, Sandip
    Dillon, Joseph S.
    Hope, Thomas A.
    Aparici, Carina Mari
    Iagaru, Andrei H.
    Hicks, Rodney J.
    Avram, Anca M.
    Strosberg, Jonathan R.
    Civelek, Ali Cahid
    Lin, Frank I.
    Pandit-Taskar, Neeta
    Pacak, Karel
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 2989 - 2995
  • [4] Cardiac Metastases of Neuroendocrine Tumors Treated With 177Lu DOTATATE Peptide Receptor Radionuclide Therapy or 131I-MIBG Therapy
    Makis, William
    McCann, Karey
    Bryanton, Mark
    McEwan, Alexander J. B.
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (12) : 962 - 964
  • [5] Impact of Kernel Truncation On 177Lu-DOTATATE and 131I-MIBG Voxelwise Dosimetry
    Graves, S.
    Tiwari, A.
    Hyer, D.
    Flynn, R.
    Buatti, J.
    Sunderland, J.
    MEDICAL PHYSICS, 2019, 46 (06) : E316 - E316
  • [6] 177Lu-DOTATATE radionuclide therapy for pediatric patients with relapsed high-risk neuroblastoma negative on 131I-MIBG imaging - a pilot study
    Chen, Sirong
    Cheung, William
    Leung, Yim Lung
    Cheng, Kam
    Wong, Ka Nin
    Wong, Yuet Hung
    Ho, Chi-Lai
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [7] Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting
    Kalshetty, Ashwini
    Ramaswamy, Anant
    Ostwal, Vikas
    Basu, Sandip
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (12) : 1143 - 1149
  • [8] Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
    Zandee, Wouter T.
    Brabander, Tessa
    Blazevic, Anela
    Minczeles, Noemie S.
    Feelders, Richard A.
    de Herder, Wouter W.
    Hofland, Johannes
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (09): : E3665 - E3672
  • [9] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL)
    Zovato, S.
    Kumanova, A.
    Dematte, S.
    Sansovini, M.
    Bodei, L.
    Di Sarra, D.
    Casagranda, E.
    Severi, S.
    Ambrosetti, A.
    Schiavi, F.
    Opocher, G.
    Paganelli, G.
    HORMONE AND METABOLIC RESEARCH, 2012, 44 (05) : 411 - 414
  • [10] Dramatic response with peptide receptor radionuclide therapy with 177Lu-DOTATATE and capecitabine in the treatment of metastatic thymic carcinoma
    Bal, C.
    Ballal, S.
    Tripati, M.
    Chakraborty, P.
    Thakral, P.
    Arora, G.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56
12345